Masatoshi Kudo, MD
Lenvatinib (Lenvima) was noninferior for overall survival (OS) while improving progression-free survival (PFS) compared with sorafenib (Nexavar) for the frontline treatment of patients with unresectable hepatocellular carcinoma (HCC), according to findings from the phase III REFLECT trial now published online in the Lancet
“Real-life experience and further data will inform us about the effect of lenvatinib in the treatment landscape. Although it is great to have a new drug in the repertoire, only time will tell if lenvatinib has changed real-life systemic treatment for hepatocellular carcinoma patients.”
- Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial [published online February 9, 2018]. Lancet. doi:10.1016/S0140-6736(18)30207-1.
- Reig M, Bruix J. Lenvatinib: can a non-inferiority trial change clinical practice? [published online February 9, 2018]. Lancet. doi: 10.1016/S0140-6736(18)30208-3.
... to read the full story